Dr. Stefanie Fischer
Medizinische Onkologie und Hämatologie · Dept. I
BRCA2 germline mutation carrier with five malignancies: a case report.
Su E, Christinat Y, McKee T, Azzarello-Burri S, Jochum W, Fischer S, Rothermundt C. BRCA2 germline mutation carrier with five malignancies: a case report. Hered Cancer Clin Pract 2024; 22:27.
Dec 19, 2024BRCA2 germline mutation carrier with five malignancies: a case report.
Dec 19, 2024Hered Cancer Clin Pract 2024; 22:27
Su Elena, Christinat Yann, McKee Thomas, Azzarello-Burri Silvia, Jochum Wolfram, Fischer Stefanie, Rothermundt Christian
Factors Guiding Clinical Decision-Making in Genitourinary Oncology.
Wosny M, Aeppli S, Fischer S, Peres T, Rothermundt C, Hastings J. Factors Guiding Clinical Decision-Making in Genitourinary Oncology. Cancer Med 2024; 13:e70304.
Oct 1, 2024Factors Guiding Clinical Decision-Making in Genitourinary Oncology.
Oct 1, 2024Cancer Med 2024; 13:e70304
Wosny Marie, Aeppli Stefanie, Fischer Stefanie, Peres Tobias, Rothermundt Christian, Hastings Janna
First Indicator of Relapse in Testicular Cancer and Implications for Follow-up: Analysis of the Swiss Austrian German Testicular Cancer Cohort Study (SAG TCCS).
Fischer S, Gillessen S, Stalder O, Terbuch A, Cathomas R, Schmid F, Zihler D, Müller-Stich B, Fankhauser C, Hirschi-Blickenstorfer A, Alex Kluth L, Seifert B, Templeton A, Mingrone W, Ufe M, Fischer N, Beyer J, Woelky R, Omlin A, Vogl U, Hoppe K, Kamradt J, Rothschild S, Rothermundt C. First Indicator of Relapse in Testicular Cancer and Implications for Follow-up: Analysis of the Swiss Austrian German Testicular Cancer Cohort Study (SAG TCCS). Eur Urol Open Sci 2024; 68:68-74.
Sep 11, 2024First Indicator of Relapse in Testicular Cancer and Implications for Follow-up: Analysis of the Swiss Austrian German Testicular Cancer Cohort Study (SAG TCCS).
Sep 11, 2024Eur Urol Open Sci 2024; 68:68-74
Fischer Stefanie, Gillessen Silke, Stalder Odile, Terbuch Angelika, Cathomas Richard, Schmid Florian, Zihler Deborah, Müller-Stich Beat P, Fankhauser Christian Daniel, Hirschi-Blickenstorfer Anita, Alex Kluth Luis, Seifert Bettina, Templeton Arnoud J, Mingrone Walter, Ufe Mark-Peter, Fischer Natalie Fischer, Beyer Jörg, Woelky Regina, Omlin Aurelius, Vogl Ursula M, Hoppe Katharina, Kamradt Jörn, Rothschild Sacha I, Rothermundt Christian
Rare histologic transformation of a CTNNB1 (β-catenin) mutated prostate cancer with aggressive clinical course.
Akhoundova D, Fischer S, Triscott J, Lehner M, Thienger P, Maletti S, Jacquet M, Lubis D, Bubendorf L, Jochum W, Rubin M. Rare histologic transformation of a CTNNB1 (β-catenin) mutated prostate cancer with aggressive clinical course. Diagn Pathol 2024; 19:83.
Jun 21, 2024Rare histologic transformation of a CTNNB1 (β-catenin) mutated prostate cancer with aggressive clinical course.
Jun 21, 2024Diagn Pathol 2024; 19:83
Akhoundova Dilara, Fischer Stefanie, Triscott Joanna, Lehner Marika, Thienger Phillip, Maletti Sina, Jacquet Muriel, Lubis Dinda S H, Bubendorf Lukas, Jochum Wolfram, Rubin Monika Afzali
Population pharmacokinetics of TLD-1, a novel liposomal doxorubicin, in a phase I trial.
Mc Laughlin A, Hess D, Michelet R, Colombo I, Haefliger S, Bastian S, Rabaglio-Poretti M, Schwitter M, Fischer S, Eckhardt K, Hayoz S, Kopp C, Klose M, Sessa C, Stathis A, Halbherr S, Huisinga W, Jörger M, Kloft C. Population pharmacokinetics of TLD-1, a novel liposomal doxorubicin, in a phase I trial. Cancer Chemother Pharmacol 2024; 94:349-360.
Jun 15, 2024Population pharmacokinetics of TLD-1, a novel liposomal doxorubicin, in a phase I trial.
Jun 15, 2024Cancer Chemother Pharmacol 2024; 94:349-360
Mc Laughlin Anna M, Hess Dagmar, Michelet Robin, Colombo Ilaria, Haefliger Simon, Bastian Sara, Rabaglio-Poretti Manuela, Schwitter Michael, Fischer Stefanie, Eckhardt Katrin, Hayoz Stefanie, Kopp Christoph, Klose Marian, Sessa Cristiana, Stathis Anastasios, Halbherr Stefan, Huisinga Wilhelm, Jörger Markus, Kloft Charlotte
Metronomic cyclophosphamide for bone marrow carcinomatosis in metastatic castration-resistant prostate cancer.
Peres T, Aeppli S, Fischer S, Gysel K, Rothermundt C. Metronomic cyclophosphamide for bone marrow carcinomatosis in metastatic castration-resistant prostate cancer. J Cancer Res Clin Oncol 2024; 150:84.
Feb 8, 2024Metronomic cyclophosphamide for bone marrow carcinomatosis in metastatic castration-resistant prostate cancer.
Feb 8, 2024J Cancer Res Clin Oncol 2024; 150:84
Peres Tobias, Aeppli Stefanie, Fischer Stefanie, Gysel Katrin, Rothermundt Christian
Prognostic Factor Risk Groups for Clinical Stage I Seminoma: An Individual Patient Data Analysis by the European Association of Urology Testicular Cancer Guidelines Panel and Guidelines Office.
Boormans J, Sylvester R, Anson-Cartwright L, Glicksman R, Hamilton R, Hahn E, Daugaard G, Lauritsen J, Wagner T, Avuzzi B, Nicolai N, del Muro X, Aparicio J, Stalder O, Rothermundt C, Fischer S, Laguna M. Prognostic Factor Risk Groups for Clinical Stage I Seminoma: An Individual Patient Data Analysis by the European Association of Urology Testicular Cancer Guidelines Panel and Guidelines Office. Eur Urol Oncol 2023
Nov 9, 2023Prognostic Factor Risk Groups for Clinical Stage I Seminoma: An Individual Patient Data Analysis by the European Association of Urology Testicular Cancer Guidelines Panel and Guidelines Office.
Nov 9, 2023Eur Urol Oncol 2023
Boormans Joost L, Sylvester Richard, Anson-Cartwright Lynn, Glicksman Rachel M, Hamilton Robert J, Hahn Ezra, Daugaard Gedske, Lauritsen Jakob, Wagner Thomas, Avuzzi Barbara, Nicolai Nicola, del Muro Xavier Garcia, Aparicio Jorge, Stalder Odile, Rothermundt Christian, Fischer Stefanie, Laguna Maria P
Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study.
Kelly W, Danila D, Lin C, Lee J, Matsubara N, Ward P, Armstrong A, Pook D, Kim M, Dorff T, Fischer S, Lin Y, Horvath L, Sumey C, Yang Z, Jurida G, Smith K, Connarn J, Penny H, Stieglmaier J, Appleman L. Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study. Cancer Discov 2023:OF1-OF14.
Oct 20, 2023Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study.
Oct 20, 2023Cancer Discov 2023:OF1-OF14
Kelly William K, Danila D C, Lin Chia-Chi, Lee Jae-Lyun, Matsubara Nobuaki, Ward Patrick J, Armstrong Andrew J, Pook David, Kim Miso, Dorff Tanya, Fischer Stefanie, Lin Yung-Chang, Horvath L G, Sumey Christopher, Yang Zhao, Jurida Gabor, Smith Kristen M, Connarn Jamie N, Penny Hweixian L, Stieglmaier Julia, Appleman Leonard J
Interdisciplinary Swiss consensus recommendations on staging and treatment of advanced prostate cancer.
Templeton A, Omlin A, Berthold D, Beyer J, Burger I, Eberli D, Engeler D, Fankhauser C, Fischer S, Gillessen S, Nicolas G, Kroeze S, Lorch A, Müntener M, Papachristofilou A, Schäfer N, Seiler D, Stenner-Liewen F, Tsantoulis P, Vlajnic T, Zilli T, Zwahlen D, Cathomas R. Interdisciplinary Swiss consensus recommendations on staging and treatment of advanced prostate cancer. Swiss Med Wkly 2023; 153:40108.
Aug 15, 2023Interdisciplinary Swiss consensus recommendations on staging and treatment of advanced prostate cancer.
Aug 15, 2023Swiss Med Wkly 2023; 153:40108
Templeton Arnoud J, Omlin Aurelius, Berthold Dominik R, Beyer Jörg, Burger Irene A, Eberli Daniel, Engeler Daniel, Fankhauser Christian Daniel, Fischer Stefanie, Gillessen Silke, Nicolas Guillaume, Kroeze Stephanie G C, Lorch Anja, Müntener Michael, Papachristofilou Alexandros, Schäfer Niklaus G, Seiler Daniel, Stenner-Liewen Frank, Tsantoulis Petros, Vlajnic Tatjana, Zilli Thomas, Zwahlen Daniel Rudolf, Cathomas Richard
Humoral and cellular BNT162b2 mRNA-based booster vaccine-induced immunity in patients with multiple myeloma and persistence of neutralising antibodies: results of a prospective single-centre cohort study.
Silzle T, Kahlert C, Albrich W, Nigg S, Demmer-Steingruber R, Driessen C, Fischer S. Humoral and cellular BNT162b2 mRNA-based booster vaccine-induced immunity in patients with multiple myeloma and persistence of neutralising antibodies: results of a prospective single-centre cohort study. Swiss Med Wkly 2023; 153:40090.
Jun 15, 2023Humoral and cellular BNT162b2 mRNA-based booster vaccine-induced immunity in patients with multiple myeloma and persistence of neutralising antibodies: results of a prospective single-centre cohort study.
Jun 15, 2023Swiss Med Wkly 2023; 153:40090
Silzle Tobias, Kahlert Christian, Albrich Werner, Nigg Susanne, Demmer-Steingruber Ruth, Driessen Christoph, Fischer Stefanie
European Association of Urology Guidelines on Testicular Cancer: 2023 Update.
Patrikidou A, Cazzaniga W, Berney D, Boormans J, de Angst I, Di Nardo D, Fankhauser C, Fischer S, Gravina C, Gremmels H, Heidenreich A, Janisch F, Leão R, Nicolai N, Oing C, Oldenburg J, Shepherd R, Tandstad T, Nicol D. European Association of Urology Guidelines on Testicular Cancer: 2023 Update. Eur Urol 2023; 84:289-301.
May 12, 2023European Association of Urology Guidelines on Testicular Cancer: 2023 Update.
May 12, 2023Eur Urol 2023; 84:289-301
Patrikidou Anna, Cazzaniga Walter, Berney Daniel, Boormans Joost L, de Angst Isabel, Di Nardo Domenico, Fankhauser Christian Daniel, Fischer Stefanie, Gravina Carmen, Gremmels Hendrik, Heidenreich Axel, Janisch Florian, Leão Ricardo, Nicolai Nicola, Oing Christoph, Oldenburg Jan, Shepherd Robert, Tandstad Torgrim, Nicol David
Patient and General Population Preferences Regarding the Benefits and Harms of Treatment for Metastatic Prostate Cancer: A Discrete Choice Experiment.
Menges D, Piatti M, Omlin A, Cathomas R, Benamran D, Fischer S, Iselin C, Kueng M, Lorch A, Prause L, Rothermundt C, O'Meara Stern A, Zihler D, Lippuner M, Braun J, Cerny T, Puhan M. Patient and General Population Preferences Regarding the Benefits and Harms of Treatment for Metastatic Prostate Cancer: A Discrete Choice Experiment. Eur Urol Open Sci 2023; 51:26-38.
Mar 22, 2023Patient and General Population Preferences Regarding the Benefits and Harms of Treatment for Metastatic Prostate Cancer: A Discrete Choice Experiment.
Mar 22, 2023Eur Urol Open Sci 2023; 51:26-38
Menges Dominik, Piatti Michela C, Omlin Aurelius, Cathomas Richard, Benamran Daniel, Fischer Stefanie, Iselin Christophe E, Kueng Marc, Lorch Anja, Prause Lukas, Rothermundt Christian, O'Meara Stern Alix, Zihler Deborah, Lippuner Max, Braun Julia, Cerny Thomas, Puhan Milo Alan
The Value of Tumour Markers in the Detection of Relapse-Lessons Learned from the Swiss Austrian German Testicular Cancer Cohort Study.
Fischer S, Rothermundt C, Stalder O, Terbuch A, Hermanns T, Zihler D, Müller-Stich B, Fankhauser C, Hirschi-Blickenstorfer A, Seifert B, Alex Kluth L, Ufe M, Mingrone W, Templeton A, Fischer N, Rothschild S, Woelky R, Gillessen S, Cathomas R. The Value of Tumour Markers in the Detection of Relapse-Lessons Learned from the Swiss Austrian German Testicular Cancer Cohort Study. Eur Urol Open Sci 2023; 50:57-60.
Feb 20, 2023The Value of Tumour Markers in the Detection of Relapse-Lessons Learned from the Swiss Austrian German Testicular Cancer Cohort Study.
Feb 20, 2023Eur Urol Open Sci 2023; 50:57-60
Fischer Stefanie, Rothermundt Christian, Stalder Odile, Terbuch Angelika, Hermanns Thomas, Zihler Deborah, Müller-Stich Beat P, Fankhauser Christian Daniel, Hirschi-Blickenstorfer Anita, Seifert Bettina, Alex Kluth Luis, Ufe Mark-Peter, Mingrone Walter, Templeton Arnoud J, Fischer Natalie Fischer, Rothschild Sacha I, Woelky Regina, Gillessen Silke, Cathomas Richard
Treatment Outcomes for Men with Clinical Stage II Nonseminomatous Germ Cell Tumours Treated with Primary Retroperitoneal Lymph Node Dissection: A Systematic Review.
Neuenschwander A, Lonati C, Antonelli L, Papachristofilou A, Cathomas R, Rothermundt C, Templeton A, Gulamhusein A, Fischer S, Gillessen S, Hermanns T, Lorch A, Mattei A, Fankhauser C. Treatment Outcomes for Men with Clinical Stage II Nonseminomatous Germ Cell Tumours Treated with Primary Retroperitoneal Lymph Node Dissection: A Systematic Review. Eur Urol Focus 2022
Nov 12, 2022Treatment Outcomes for Men with Clinical Stage II Nonseminomatous Germ Cell Tumours Treated with Primary Retroperitoneal Lymph Node Dissection: A Systematic Review.
Nov 12, 2022Eur Urol Focus 2022
Neuenschwander Anne, Lonati Chiara, Antonelli Luca, Papachristofilou Alexandros, Cathomas Richard, Rothermundt Christian, Templeton Arnoud J, Gulamhusein Aziz, Fischer Stefanie, Gillessen Silke, Hermanns Thomas, Lorch Anja, Mattei Agostino, Fankhauser Christian D
A Case of Sustained Tumor Regression With MP0274, a Novel DARPin Therapeutic Targeting Human Epidermal Growth Factor Receptor 2 Signaling, in Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Prior Trastuzumab and Pertuzumab.
Fischer S, Götze T, Omlin A, Baird R, Dawson K, Zitt C, Arany Z, Tresch G, Fiedler U, Jeger S, Fung S, Legenne P, Leupin N, Schneeweiss A, Fremd C. A Case of Sustained Tumor Regression With MP0274, a Novel DARPin Therapeutic Targeting Human Epidermal Growth Factor Receptor 2 Signaling, in Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Prior Trastuzumab and Pertuzumab. JCO Precis Oncol 2022; 6:e2200006.
Nov 1, 2022A Case of Sustained Tumor Regression With MP0274, a Novel DARPin Therapeutic Targeting Human Epidermal Growth Factor Receptor 2 Signaling, in Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer After Prior Trastuzumab and Pertuzumab.
Nov 1, 2022JCO Precis Oncol 2022; 6:e2200006
Fischer Stefanie, Götze Thorsten O, Omlin Aurelius, Baird Richard D, Dawson Keith M, Zitt Christof, Arany Zita, Tresch Gaby, Fiedler Ulrike, Jeger Simone, Fung Samson, Legenne Philippe, Leupin Nicolas, Schneeweiss Andreas, Fremd Carlo
Incidence and outcome of patients with renal cell carcinoma treated with partial or radical nephrectomy in the Cantons St Gallen and Appenzell 2009-2018.
Aeppli S, Engeler D, Fischer S, Omlin A, Pratsinis M, Hermann C, Rothermundt C. Incidence and outcome of patients with renal cell carcinoma treated with partial or radical nephrectomy in the Cantons St Gallen and Appenzell 2009-2018. Swiss Med Wkly 2022; 152:w30175.
Jun 16, 2022Incidence and outcome of patients with renal cell carcinoma treated with partial or radical nephrectomy in the Cantons St Gallen and Appenzell 2009-2018.
Jun 16, 2022Swiss Med Wkly 2022; 152:w30175
Aeppli Stefanie, Engeler Daniel, Fischer Stefanie, Omlin Aurelius, Pratsinis Manolis, Hermann Christian, Rothermundt Christian
Patterns of Disease Progression and Outcome of Patients With Testicular Seminoma Who Relapse After Adjuvant or Curative Radiation Therapy.
Terbuch A, Posch F, Bauernhofer T, Jost P, Partl R, Stranzl-Lawatsch H, Baciarello G, Fizazi K, Giannatempo P, Verzoni E, Sweeney C, Ravi P, Tran B, Basso U, White J, Vincenzi B, Oing C, Cutuli H, Dieckmann K, Gamulin M, Chovanec M, Fankhauser C, Heidenreich A, Mohamad O, Thibault C, Fischer S, Gillessen S. Patterns of Disease Progression and Outcome of Patients With Testicular Seminoma Who Relapse After Adjuvant or Curative Radiation Therapy. Int J Radiat Oncol Biol Phys 2022; 113:825-832.
Apr 20, 2022Patterns of Disease Progression and Outcome of Patients With Testicular Seminoma Who Relapse After Adjuvant or Curative Radiation Therapy.
Apr 20, 2022Int J Radiat Oncol Biol Phys 2022; 113:825-832
Terbuch Angelika, Posch Florian, Bauernhofer Thomas, Jost Philipp J, Partl Richard, Stranzl-Lawatsch Heidi, Baciarello Giulia, Fizazi Karim, Giannatempo Patrizia, Verzoni Elena, Sweeney Christopher, Ravi Praful, Tran Ben, Basso Umberto, White Jeff, Vincenzi Bruno, Oing Christoph, Cutuli Hernan Javier, Dieckmann Klaus Peter, Gamulin Marija, Chovanec Michal, Fankhauser Christian Daniel, Heidenreich Axel, Mohamad Osama, Thibault Constance, Fischer Stefanie, Gillessen Silke
Peritoneal carcinosis in male germ cell tumor patients: a registry study compiled by the German Testicular Cancer Study Group (GTCSG).
Seidel C, Hentrich M, Zschäbitz S, Paffenholz P, Heidenreich A, Nestler T, Tran B, Fischer S, Daugaard G, Ochsenreither S, Brito M, Zengerling F, Schwab C, Bokemeyer C, Oing C. Peritoneal carcinosis in male germ cell tumor patients: a registry study compiled by the German Testicular Cancer Study Group (GTCSG). World J Urol 2022; 40:355-361.
Jan 7, 2022Peritoneal carcinosis in male germ cell tumor patients: a registry study compiled by the German Testicular Cancer Study Group (GTCSG).
Jan 7, 2022World J Urol 2022; 40:355-361
Seidel Christoph, Hentrich Marcus, Zschäbitz Stefanie, Paffenholz Pia, Heidenreich Axel, Nestler Tim, Tran Ben, Fischer Stefanie, Daugaard Gedske, Ochsenreither Sebastian, Brito Margarida, Zengerling Friedemann, Schwab Constantin, Bokemeyer Carsten, Oing Christoph
Metastatic Prostate Cancer: Treatment Options.
Achard V, Putora P, Omlin A, Zilli T, Fischer S. Metastatic Prostate Cancer: Treatment Options. Oncology 2021; 100:48-59.
Nov 15, 2021Metastatic Prostate Cancer: Treatment Options.
Nov 15, 2021Oncology 2021; 100:48-59
Achard Vérane, Putora Paul Martin, Omlin Aurelius, Zilli Thomas, Fischer Stefanie
Swiss germ-cell cancer consensus recommendations
Beyer J, Stenner F, Spahn M, Seiler R, Rothermundt C, Roth B, Papachristofilou A, Omlin A, Lorch A, Honecker F, Hermanns T, Gross T, Gillessen S, Fischer S, Fankhauser C, Cathomas R, Bode P, Berthold D, Bührer E. Swiss germ-cell cancer consensus recommendations. Swiss Med Wkly 2021; 151
Aug 23, 2021Swiss germ-cell cancer consensus recommendations
Aug 23, 2021Swiss Med Wkly 2021; 151
Beyer Jörg, Stenner Frank, Spahn Martin, Seiler Roland, Rothermundt Christian, Roth Beat, Papachristofilou Alexandros, Omlin Aurelius, Lorch Anja, Honecker Friedemann, Hermanns Thomas, Gross Tobias, Gillessen Silke, Fischer Stefanie, Fankhauser Christian D, Cathomas Richard, Bode Peter-Karl, Berthold Dominik, Bührer Emanuel